BREXAFEMME Drug Patent Profile
✉ Email this page to a colleague
When do Brexafemme patents expire, and when can generic versions of Brexafemme launch?
Brexafemme is a drug marketed by Scynexis and is included in one NDA. There are five patents protecting this drug.
This drug has fifty-two patent family members in twenty-six countries.
The generic ingredient in BREXAFEMME is ibrexafungerp citrate. One supplier is listed for this compound. Additional details are available on the ibrexafungerp citrate profile page.
DrugPatentWatch® Generic Entry Outlook for Brexafemme
Brexafemme will be eligible for patent challenges on June 1, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 19, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BREXAFEMME?
- What are the global sales for BREXAFEMME?
- What is Average Wholesale Price for BREXAFEMME?
Summary for BREXAFEMME
International Patents: | 52 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 11 |
Drug Prices: | Drug price information for BREXAFEMME |
What excipients (inactive ingredients) are in BREXAFEMME? | BREXAFEMME excipients list |
DailyMed Link: | BREXAFEMME at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BREXAFEMME
Generic Entry Date for BREXAFEMME*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for BREXAFEMME
Drug Class | Triterpenoid Antifungal |
Mechanism of Action | Glucan Synthase Inhibitors |
US Patents and Regulatory Information for BREXAFEMME
BREXAFEMME is protected by six US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of BREXAFEMME is ⤷ Try for Free.
This potential generic entry date is based on patent ⤷ Try for Free.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BREXAFEMME
When does loss-of-exclusivity occur for BREXAFEMME?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Croatia
Patent: 0220544
Estimated Expiration: ⤷ Try for Free
Cyprus
Patent: 25272
Estimated Expiration: ⤷ Try for Free
Denmark
Patent: 47711
Estimated Expiration: ⤷ Try for Free
Eurasian Patent Organization
Patent: 6874
Estimated Expiration: ⤷ Try for Free
Patent: 1791645
Estimated Expiration: ⤷ Try for Free
European Patent Office
Patent: 47711
Estimated Expiration: ⤷ Try for Free
Patent: 39684
Estimated Expiration: ⤷ Try for Free
Hong Kong
Patent: 47196
Estimated Expiration: ⤷ Try for Free
Hungary
Patent: 58721
Estimated Expiration: ⤷ Try for Free
Lithuania
Patent: 47711
Estimated Expiration: ⤷ Try for Free
Poland
Patent: 47711
Estimated Expiration: ⤷ Try for Free
Portugal
Patent: 47711
Estimated Expiration: ⤷ Try for Free
San Marino
Patent: 02200202
Estimated Expiration: ⤷ Try for Free
Serbia
Patent: 234
Estimated Expiration: ⤷ Try for Free
Slovenia
Patent: 47711
Estimated Expiration: ⤷ Try for Free
Spain
Patent: 13111
Estimated Expiration: ⤷ Try for Free
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering BREXAFEMME around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2016118396 | ⤷ Try for Free | |
South Korea | 20200044823 | 산성 pH에서 증진된 활성을 갖는 항진균제 | ⤷ Try for Free |
Portugal | 3247711 | ⤷ Try for Free | |
Spain | 2932658 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Market Dynamics and Financial Trajectory for BREXAFEMME
More… ↓